BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1803 related articles for article (PubMed ID: 26209535)

  • 41. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK; Eapen A; Birch H; Kurinchi-Selvan A; Lockwood G
    Reprod Biomed Online; 2014 Nov; 29(5):552-8. PubMed ID: 25246126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Luteal phase support in in vitro fertilization.
    Yanushpolsky EH
    Semin Reprod Med; 2015 Mar; 33(2):118-27. PubMed ID: 25734349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve.
    Friis Wang N; Bogstad JW; Pors SE; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
    Hum Reprod; 2023 Apr; 38(4):716-725. PubMed ID: 36721920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve.
    Friis Wang N; Bogstad JW; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
    Hum Reprod; 2023 Sep; 38(9):1807-1815. PubMed ID: 37354554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Live birth rates after IVF are reduced by both low and high progesterone levels on the day of human chorionic gonadotrophin administration.
    Santos-Ribeiro S; Polyzos NP; Haentjens P; Smitz J; Camus M; Tournaye H; Blockeel C
    Hum Reprod; 2014 Aug; 29(8):1698-705. PubMed ID: 24939956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization.
    Thuesen LL; Loft A; Egeberg AN; Smitz J; Petersen JH; Andersen AN
    Hum Reprod; 2012 Oct; 27(10):3074-84. PubMed ID: 22791754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG.
    Vuong LN; Pham TD; Ho VNA; Ho TM; Humaidan P; Andersen CY
    Front Endocrinol (Lausanne); 2020; 11():137. PubMed ID: 32265836
    [No Abstract]   [Full Text] [Related]  

  • 50. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
    Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
    Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
    Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
    Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
    Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
    Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.
    Humaidan P; Bungum L; Bungum M; Yding Andersen C
    Reprod Biomed Online; 2006 Aug; 13(2):173-8. PubMed ID: 16895629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of early versus late initiation of GnRH antagonist co-treatment for controlled ovarian stimulation in IVF: a randomized controlled trial.
    Hamdine O; Macklon NS; Eijkemans MJ; Laven JS; Cohlen BJ; Verhoeff A; van Dop PA; Bernardus RE; Lambalk CB; Oosterhuis GJ; Holleboom CA; van den Dool-Maasland GC; Verburg HJ; van der Heijden PF; Blankhart A; Fauser BC; Broekmans FJ;
    Hum Reprod; 2013 Dec; 28(12):3227-35. PubMed ID: 24129613
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of blastocyst euploidy rates following luteal versus follicular phase stimulation in a GnRH antagonist protocol: a prospective study with repeated ovarian stimulation cycles.
    Martinez F; Clua E; Roca M; Garcia S; Polyzos NP
    Hum Reprod; 2022 Nov; 37(12):2777-2786. PubMed ID: 36269092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.